China's National Development and Reform Commission (NDRC) formally announced an investigation into drug and medical device pricing among domestic and foreign firms. The program is already underway: earlier this month Pfizer was summoned to the agency to discuss undisclosed pricing issues, though neither side has discussed anything about the conversation. The NDRC said it would look into unusual fluctuations in price, which no doubt implies a focus on upward movements.
